145 related articles for article (PubMed ID: 9792992)
1. Endothelin-1 receptor antagonism does not influence myocardial function in hypertensive dogs.
Massart PE; Hodeige D; Van Mechelen H; Heyndrickx GR; Donckier J
Eur J Clin Invest; 1998 Oct; 28(10):798-806. PubMed ID: 9792992
[TBL] [Abstract][Full Text] [Related]
2. Additional hypotensive effect of endothelin-1 receptor antagonism in hypertensive dogs under angiotensin-converting enzyme inhibition.
Donckier JE; Massart PE; Hodeige D; Van Mechelen H; Clozel JP; Laloux O; Ketelslegers JM; Charlier AA; Heyndrickx GR
Circulation; 1997 Aug; 96(4):1250-6. PubMed ID: 9286956
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II and endothelin-1 receptor antagonists have cumulative hypotensive effects in canine Page hypertension.
Massart PE; Hodeige DG; Van Mechelen H; Charlier AA; Ketelslegers JM; Heyndrickx GR; Donckier JE
J Hypertens; 1998 Jun; 16(6):835-41. PubMed ID: 9663924
[TBL] [Abstract][Full Text] [Related]
4. Role of endogenous endothelin-1 in experimental renal hypertension in dogs.
Donckier J; Stoleru L; Hayashida W; Van Mechelen H; Selvais P; Galanti L; Clozel JP; Ketelslegers JM; Pouleur H
Circulation; 1995 Jul; 92(1):106-13. PubMed ID: 7788903
[TBL] [Abstract][Full Text] [Related]
5. Acute effects of an endothelin-1 receptor antagonist bosentan at different stages of heart failure in conscious dogs.
Choussat R; Hittinger L; Barbe F; Maistre G; Carayon A; Crozatier B; Su J
Cardiovasc Res; 1998 Sep; 39(3):580-8. PubMed ID: 9861300
[TBL] [Abstract][Full Text] [Related]
6. Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling.
Fraccarollo D; Hu K; Galuppo P; Gaudron P; Ertl G
Circulation; 1997 Dec; 96(11):3963-73. PubMed ID: 9403621
[TBL] [Abstract][Full Text] [Related]
7. Endothelin B receptor-mediated vasoconstriction induced by endothelin A receptor antagonist.
Zhang Y; Oliver JR; Horowitz JD
Cardiovasc Res; 1998 Sep; 39(3):665-73. PubMed ID: 9861310
[TBL] [Abstract][Full Text] [Related]
8. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling.
Mulder P; Richard V; Derumeaux G; Hogie M; Henry JP; Lallemand F; Compagnon P; Macé B; Comoy E; Letac B; Thuillez C
Circulation; 1997 Sep; 96(6):1976-82. PubMed ID: 9323089
[TBL] [Abstract][Full Text] [Related]
9. Hemodynamic effect of endothelin antagonists in dogs with myocardial infarction.
Ohta H; Suzuki J; Akima T; Kawai N; Hanada K; Nishikibe M
J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S255-7. PubMed ID: 9595453
[TBL] [Abstract][Full Text] [Related]
10. Short-term hemodynamic effects of endothelin receptor blockade in dogs with chronic heart failure.
Shimoyama H; Sabbah HN; Borzak S; Tanimura M; Shevlyagin S; Scicli G; Goldstein S
Circulation; 1996 Aug; 94(4):779-84. PubMed ID: 8772702
[TBL] [Abstract][Full Text] [Related]
11. Bosentan the mixed endothelin-A- and -B-receptor antagonist suppresses intrapericardial endothelin-1-induced ventricular arrhythmias.
Horkay F; Gellér L; Kiss O; Szabó T; Vagó H; Kékesi V; Juhász-Nagy A; Merkely B
J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S320-2. PubMed ID: 11078409
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic role of bosentan in hypertension: lessons from the model of perinephritic hypertension.
Donckier JE
Heart Fail Rev; 2001 Dec; 6(4):253-64. PubMed ID: 11447300
[TBL] [Abstract][Full Text] [Related]
13. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators.
Krum H; Viskoper RJ; Lacourciere Y; Budde M; Charlon V
N Engl J Med; 1998 Mar; 338(12):784-90. PubMed ID: 9504938
[TBL] [Abstract][Full Text] [Related]
14. Bosentan prevents hypoxia-reoxygenation-induced pulmonary hypertension and improves pulmonary function.
Pearl JM; Wellmann SA; McNamara JL; Lombardi JP; Wagner CJ; Raake JL; Nelson DP
Ann Thorac Surg; 1999 Nov; 68(5):1714-21; discussion 1721-2. PubMed ID: 10585047
[TBL] [Abstract][Full Text] [Related]
15. Endothelin receptor blockade reduces ventricular dysfunction and injury after reoxygenation.
Pearl JM; Nelson DP; Wagner CJ; Lombardi JP; Duffy JY
Ann Thorac Surg; 2001 Aug; 72(2):565-70. PubMed ID: 11515898
[TBL] [Abstract][Full Text] [Related]
16. Endothelin blockade in angiotensin II hypertension: prevention and treatment studies in the rat.
Ficai S; Herizi A; Mimran A; Jover B
Clin Exp Pharmacol Physiol; 2001 Dec; 28(12):1100-3. PubMed ID: 11903325
[TBL] [Abstract][Full Text] [Related]
17. Chronic endothelin receptor blockade prevents renal vasoconstriction and sodium retention in rats with chronic heart failure.
Ding SS; Qiu C; Hess P; Xi JF; Clozel JP; Clozel M
Cardiovasc Res; 2002 Mar; 53(4):963-70. PubMed ID: 11922906
[TBL] [Abstract][Full Text] [Related]
18. Endogenous endothelin modulates blood pressure, plasma volume, and albumin escape after systemic nitric oxide blockade.
Filep JG
Hypertension; 1997 Jul; 30(1 Pt 1):22-8. PubMed ID: 9231816
[TBL] [Abstract][Full Text] [Related]
19. Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade.
Herizi A; Jover B; Bouriquet N; Mimran A
Hypertension; 1998 Jan; 31(1):10-4. PubMed ID: 9449383
[TBL] [Abstract][Full Text] [Related]
20. Beneficial effects of the endothelin receptor antagonist bosentan on myocardial and endothelial injury following ischaemia/reperfusion in the rat.
Li XS; Wang QD; Pernow J
Eur J Pharmacol; 1995 Sep; 283(1-3):161-8. PubMed ID: 7498305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
